Hematology
7.5K views | +3 today
Follow
 
Scooped by Gilbert C FAURE
onto Hematology
Scoop.it!

Philadelphia chromosome-negative acute lymphoblastic leukemia: ther... - PubMed - NCBI

Future Oncol. 2014 Nov;10(14):2201-12. doi: 10.2217/fon.14.81.
Gilbert C FAURE's insight:

therapies under development

more...
No comment yet.
Hematology
Diagnosis, Therapy, Follow-up
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Hematology, or Haematology

... was a major interest for our lab, during many years in the context of the GEIL still thriving, then EGIL, then European Leukemia Net.

 

Gilbert C FAURE's insight:

Hospital choices did not allow to pursue the efforts locally...

but to stay informed and allow others to surf the information wave....

 

Much information is available in the cloud, focusing on immunophenotyping of leukemias, and also on other haematology topics.


Blood cells being also immunocompetent cells, other topics curated should be of interest

http://www.scoop.it/t/immunology

http://www.scoop.it/t/from-flow-cytometry-to-cytomics

http://www.scoop.it/t/immunology-and-biotherapies

 

 

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression | Immunology

Frontiers | Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression | Immunology | Hematology | Scoop.it
Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells and local microenvironment. Multiple myeloma (MM) is a paradigm disease in which anti-tumor immunity is selectively impaired at the tumor site. By interrogating the immune reactivity of bone marrow (BM) Vγ9Vδ2 T cells to phosphoantigens, we have revealed a very early and long-lasting impairment of Vγ9Vδ2 T-cell immune functions which is already detectable in monoclonal gammopathy of undetermined significance (MGUS) and not fully reverted even in clinical remission after autologous stem cell transplantation. Multiple cell subsets [MM cells, myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), BM-derived stromal cells (BMSC)] are involved in Vγ9Vδ2 T-cell inhibition via several immune suppressive mechanisms including the redundant expression of multiple immune checkpoints (ICP). This review will address some aspects related to the dynamics of ICP expression in the BM of MM patients in relationship to the disease status (MGUS, diagnosis, remission, relapse) and how this multifaceted ICP expression impairs Vγ9Vδ2 T-cell function. We will also provide some suggestions how to rescue Vγ9Vδ2 T cells from the immune suppression operated by ICP and to recover thei
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Toxicities associated with immunotherapies for hematologic malignancies - ScienceDirect

Toxicities associated with immunotherapies for hematologic malignancies - ScienceDirect | Hematology | Scoop.it
Abstract
Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this review we provide an overview of the toxicity of some of these revolutionary agents including bispecific T cell engagers, checkpoint inhibitors, chimeric antigen receptor T-cells.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia | Hematology | Scoop.it
![Figure][1]</img>



Publisher's Note: There is a [ Blood Commentary][2] on this article in this issue.[1]: pending:yes [2]: /lookup/doi/10.1182/blood-2018-05-850248...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Leukaemia hijacks a neural mechanism to invade the central nervous system

Leukaemia hijacks a neural mechanism to invade the central nervous system | Hematology | Scoop.it
Expression of α6 integrin enables acute lymphoblastic leukaemia cells to use neural migratory pathways to invade the central nervous system and metastasize to the brain.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Differential Diagnosis and Bone Marrow Evaluation of New-Onset Pancytopenia | American Journal of Clinical Pathology | Oxford Academic

Differential Diagnosis and Bone Marrow Evaluation of New-Onset Pancytopenia | American Journal of Clinical Pathology | Oxford Academic | Hematology | Scoop.it
Abstract. New-onset pancytopenia can be caused by a wide variety of etiologies, leading to a diagnostic dilemma.These etiologies range from congenital bone ma...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

EMA CHMP recommends approval of Cablivi (caplacizumab, Sanofi/Ablynx) for a rare blood disorder called acquired thrombotic thrombocytopenic purpura

EMA CHMP recommends approval of Cablivi (caplacizumab, Sanofi/Ablynx) for a rare blood disorder called acquired thrombotic thrombocytopenic purpura | Hematology | Scoop.it

The European Medicines Agency’s Committee for
Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi was developed by Ablynx, a Sanofi Company.

 

Directed against von Willebrand Factor (vWF), Cablivi is Ablynx’s first Nanobody®-based
medicine to receive a positive CHMP opinion and, if approved, will be the first therapeutic
specifically indicated for the treatment of aTTP.

 

The potential of Cablivi to address
this unmet need has been demonstrated in 220 patients with aTTP, who participated in
the phase II TITAN and phase III HERCULES studies. Data from the TITAN study were
published in the New England Journal of Medicine in February 2016 and the positive
HERCULES results were presented at the 59th Annual Meeting of the American Society
of Hematology (ASH) in December 2017.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 4, 2:23 AM

Caplacizumab mode of action
Caplacizumab is a highly potent and selective bivalent anti-vWF Nanobody that received Orphan Drug Designation in the US and EU in 2009. It could be the first drug specifically approved for the treatment of acquired TTP.

Caplacizumab inhibits the interaction between vWF and platelets by targeting the A1 domain of vWF and thus has the potential to immediately block the ULvWF mediated platelet interactions and the formation of the string-like clots in the blood of patients with acquired TTP.

Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Single-cell transcriptomics reveal the dynamic of haematopoietic stem cell production in the aorta

Single-cell transcriptomics reveal the dynamic of haematopoietic stem cell production in the aorta | Hematology | Scoop.it
Haematopoietic stem cells (HSCs) are generated from haemogenic endothelial (HE) cells in vertebrate embryo aortas. Here, the authors perform single-cell RNA-sequencing of cells isolated from embryonic mouse aortas to identify genes and transcription factor networks activated during the...

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

European Haematology Association (EHA) Conference

European Haematology Association (EHA) Conference | Hematology | Scoop.it
Last week, I was in Sweden at the 23rd annual congress of the European Haematology Association (EHA). It is one of the biggest scientific updates of the year, with around 11,000 people attending. The conference ran over three days (Friday to Sunday) and there were numerous sessions on at the same...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Immunology and Biotherapies
Scoop.it!

Antibody Therapy and Its Expanding Role in Myeloma Treatment

Antibody Therapy and Its Expanding Role in Myeloma Treatment | Hematology | Scoop.it
Join us for a FREE webinar designed to meet the educational needs of multiple myeloma patients and their caregivers. For patients with multiple myeloma and their caregivers, the fast-growing number of treatment options can be overwhelming. The importance of staying current on new developments in myeloma research and treatment has never been greater. Among the most exciting areas of myeloma research are treatments that work with a patient’s immune system to fight myeloma (immunotherapies). Currently, several antibody therapies (monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers [BiTEs]) are under study and are showing encouraging results. We invite you to join us for this webinar to learn about antibody therapy. This webinar takes a look at some of these new agents and discusses how they have performed in clinical trials. Myeloma patients and their caregivers are sure to find this information helpful as they make future treatment decisions with their care team. There is no fee for participating in this webinar. To register, please add this event to your cart and complete the required information on the checkout page.   If you are unable to register online or do not receive a confirmation email after registering (don't forget to check your spam folder), please contact our Registration Desk at 866-872-5840 (international callers please dial 617-502-2061). You can also contact us by ✉ email

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Chronic Lymphocytic Leukemia: FDA Updates - LRF

Chronic Lymphocytic Leukemia: FDA Updates - LRF | Hematology | Scoop.it
There are many chronic lymphocytic leukemia treatment options. The choice of treatment will depend on the patients condition.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Balanced signaling cues to guide cell transitions in the blood lineage continuum - Jeroen Roose

Balanced signaling cues to guide cell transitions in the blood lineage continuum - Jeroen Roose | Hematology | Scoop.it
Blood cells need to self-renew, proliferate, and differentiate in a balanced fashion to enable self-sustaining blood systems such as the immune system. The biochemical signaling network tha
more...
No comment yet.
Rescooped by Gilbert C FAURE from Immunology and Biotherapies
Scoop.it!

Current overview and treatment of mantle cell lymphoma - F1000Research

Current overview and treatment of mantle cell lymphoma - F1000Research | Hematology | Scoop.it
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability | Hematology | Scoop.it
Article
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels | Hematology | Scoop.it
Brief Communication...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production

Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production | Hematology | Scoop.it
Clinical-scale generation of platelets from human-induced pluripotent stem cells can
be achieved in bioreactors when turbulence is factored in as an important physical
regulator of thrombopoiesis.
more...
No comment yet.
Suggested by LIGHTING
Scoop.it!

Prediction of acute myeloid leukaemia risk in healthy individuals

Prediction of acute myeloid leukaemia risk in healthy individuals | Hematology | Scoop.it
Individuals who are at high risk of developing acute myeloid leukaemia can be identified years before diagnosis using genetic information from blood samples.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Oncotarget | Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 bright NK cell subpopulations in patients with acute myeloid leukemia...

Oncotarget | Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 bright NK cell subpopulations in patients with acute myeloid leukemia... | Hematology | Scoop.it
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation...

Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from PARP Inhibitors Cancer Review
Scoop.it!

Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia

Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia | Hematology | Scoop.it

us to hypothesize that BCR-ABLp210 may function, in part, via epigenetic mechanisms that prime the tumor stem cell for malignant myeloid differentiation [...] This provides, to our knowledge, the first experimental evidence that epigene


Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Neural Crossroads in the Hematopoietic Stem Cell Niche

Neural Crossroads in the Hematopoietic Stem Cell Niche | Hematology | Scoop.it
The hematopoietic stem cell (HSC) niche supports steady-state hematopoiesis and responds
to changing needs during stress and disease. The nervous system is an important regulator
of the niche, and its influence is established early in development when stem cells
are specified.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cancers | Free Full-Text | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

Cancers | Free Full-Text | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach | Hematology | Scoop.it
Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged &gt;65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. - PubMed - NCBI

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. - PubMed - NCBI | Hematology | Scoop.it
Blood Adv. 2018 Jun 12;2(11):1250-1258. doi: 10.1182/bloodadvances.2017014373.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation

Article...
more...
No comment yet.